Imidazole-derivatives having agonistic or antagonistic activity on the histamine H3-receptor

Abstract

This application is a continuation-in-part of U.S. patent application Ser. No. 08/108,621, filed Oct. 6, 1993 now abandoned and entitled "IMIDAZOLE-DERIVATIVES HAVING AGONISTIC OR ANTAGONISTIC ACTIVITY ON THE HISTAMINE H.sub.3 -RECEPTOR".

Description

The invention relates to novel imidazole derivatives. The invention in particular relates to novel imidazole-derivatives having agonistic or antagonistic activity on the histamine H.sub.3 -receptor. More in particular it relates to isothiourea-, guanidine- and amidine-derivatives. The invention further relates to the synthesis of such compounds, a pharmaceutical composition comprising such compounds or pharmacological acceptable salts thereof, the use of the compounds as agents having biological activity, as agents with agonistic or antagonistic activity of the histamines H.sub.3 -receptor or for preparing a pharmaceutical composition.

In addition to the already longer known histamine H.sub.1 - and H.sub.2 - receptors there is also a third type histamine-receptor present in the human body, the so-called H.sub.3 -receptor. The H.sub.3 -receptor is a presynaptic receptor, i.e. it is located on a cell releasing histamine and stimulation of the receptor leads to inhibition of the histamine-release. Furthermore stimulation of the H.sub.3 - receptor influences also the release of other neurotransmitters, such as e.g. serotonine and acetylcholine. H.sub.3 -receptors are located in the central and peripheral nervous system, the lung tissue, the intestine and probably also in the spleen, the skin and the gastro-intestinal tract. A number of compounds having an effect on H.sub.3 -receptors has already been described. For a review see Schwartz et al., Agents and Actions 30, 1/2 (1990) p.13-23.

Chemical compounds can stimulate or inhibit the histamine H.sub.3 -receptor (Timmerman, J. Med. Chem. 33, p. 4-11 (1990)). Now a group of new imidazole-derivatives showing an agonistic or antagonistic activity on the histamine H.sub.3 -receptors has been found.

These derivatives are represented by the general formula: ##STR2## wherein:

Z is a group of the formula (CH.sub.2).sub.m, wherein m=1-5;

X is S or NH;

R.sub.1 is hydrogen, (C.sub.1 -C.sub.3)alkyl-, aryl(C.sub.1 -C.sub.10) alkyl, aryl or diaryl (C.sub.1 -C.sub.10) alkyl wherein aryl may be substituted with substituents selected from the group consisting of F, Cl, Br, I, --CH.sub.3, --OCH.sub.3 and --NO.sub.2, (C.sub.5 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.10)-, or a group of the formula: ##STR3## wherein r=1-4,

R.sub.8 is aryl, aryl(C.sub.1 -C.sub.10)alkyl-,

(C.sub.5 -C.sub.7)cycloalkyl- or (C.sub.5 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.10)alkyl-; and

R.sub.9 is hydrogen, (C.sub.1 -C.sub.10) alkyl- or aryl;

R.sub.2 and R.sub.5 are each hydrogen, (C.sub.1 -C.sub.3)alkyl-, aryl or arylalkyl-; R.sub.3 is hydrogen, (C.sub.1 -C.sub.3) alkyl, aryl or arylalkyl; and R.sub.4 is hydrogen, amino-, nitro-, cyano-, halogen, (C.sub.1 -C.sub.3)alkyl-, aryl or arylalkyl;

or pharmacologically acceptable salts thereof; with the proviso that

a) when X is NH and m=2 or 3, then R.sub.1 is not aryl(C.sub.3 -C.sub.4)alkyl;

b) when X is NH and m is 4, then R.sub.1 is not phenylethyl;

c) when X is NH and m=2, 3 or 4, then R.sub.1 is not (C.sub.1 -C.sub.3)alkyl;

d) when X is S and m=1, 3 or 4, then R.sub.1 is not hydrogen or (C.sub.1 -C.sub.3)alkyl; and

e) when X is S and m=2, R.sub.1 is not hydrogen, (C.sub.1 -C.sub.3) alkyl or benzyl.

S-�2-(4-imidazolyl)ethyl!isothiourea shows a strong agonistic activity and is therefore preferred as the active ingredient in a pharmaceutical composition having histamine H.sub.3 -agonistic activity.

Antagonistic activity is in particular shown by compounds of formula I, wherein R.sub.3, R.sub.4 and R.sub.5 are hydrogen; m is 2 or 3, R.sub.1 is a group of the formula --(CH.sub.2).sub.n R.sub.10, wherein R.sub.10 is aryl or substituted aryl, n.gtoreq.1and X is S or NH. Preferred compounds are:

S-�2-(imidazol-4-yl)ethyl!-N-(2-phenylethyl)-isothiourea, N-benzyl-S-�3-(4(5)-imidazolyl)propyl!isothiourea, S-�3-(4(5)-imidazolyl)propyl!-N-(2-phenylethyl)isothiourea, S-�3-(4(5)-imidazolyl)propyl!-N-(3-phenylpropyl)isothiourea, S-�3-(4(5)-imidazolyl)propyl!-N-(4-phenylbutyl)isothiourea, S-�3-(4(5)-imidazolyl)propyl!-N-(4-chlorobenzyl)isothiourea, N-cyclohexylmethyl-S-�3-(4(5)-imidazolyl)propyl!isothiourea, S-�3-(4(5)-imidazoly)propyl!-N-�2-(4-iodophenyl)ethyl!-isothiourea, N-(4-fluorobenzyl)-S-�3-(4(5)-imidazolyl)propyl!-isothiourea.2HBr N-�2-(4-chlorophenyl)ethyl!-S-�3-(4(5)imidazolyl)propyl!isothiorea.2HBr N-(4-bromobenzyl)-S-�3-(4(5)-imidazolyl)propyl!isothiourea.2HBr N-�2-(4-bromophenyl)ethyl!-S-�3-(4(5)-imidazolyl)propyl!isothiourea.2HBr N-(4-iodobenzyl)-S-�3-(4(5)-imidazolyl)propyl!isothiourea.2HBr N-�2-(4-iodophenyl)ethyl!-S-�3-(4(5)-imidazolyl)propyl!isothiourea.2HBr S-�3-(4(5)-imidazolyl)propyl!-N-(4-methylbenzyl) isothiourea.2HBr S-�3-(4(5)-imidazolyl)propyl!-N-�2-(4-methylphenyl) ethyl!isothiourea.2HBr S-�3-(4(5)-imidazolyl)propyl!-N-�2-(4-methoxybenzyl) isothiourea.2HBr S-�3-(4(5)-imidazolyl)propyl!-N-�2-(4-methoxyphenyl) ethyl)!isothiourea.2HBr N-(3,4-dichlorobenzyl)-S-�3-(4(5)-imidazolyl)propyl!isothiourea.2HBr N-benzyl-S-�4-(4(5)-imidazolyl)butyl!isothiourea dipicrate N-(2-phenylethyl)-S-�4-(4(5)-imidazolyl)butyl!isothiourea dipicrate

Other compounds showing strong antagonistic activity are compounds of formula I, wherein R.sub.3, R.sub.4 and R.sub.5 are hydrogen, m is 1, 2 or 3; and R.sub.1 is a group of the formula ##STR4## wherein .phi. is aryl, r is 1, 2 or 3; and R.sub.11 is hydrogen, (C.sub.1 -C.sub.10) alkyl- or aryl. A preferred compound is N-�2-(benzylthio)ethyl!-S-�3-(imidazol-4-yl)propyl!isothiourea.

Compounds of formula I can in general be synthesized in a for analogous compounds known manner. Favourable methods for synthesizing consist in condensation of a imidazole-compound of the general formula: ##STR5## wherein Y represents BR, OH, or O-alkyl, with a thiourea-derivative having the general formula: ##STR6## or condensation of a imidazole of formula II wherein Y represents NH.sub.2, with a isothiourea-derivative having the general formula: ##STR7## wherein in the formulas III and IV R represents hydrogen, (C.sub.1 -C.sub.10)alkyl-, aryl(C.sub.1 -C.sub.10)alkyl- or aryl, and R.sub.12 represents (C.sub.1 -C.sub.10)alkyl. As solvents polar solvents are used such as ethanol or propanol. The condensations are carried out at temperatures between room temperature and the boiling point of the solvents for between 30 minutes and 10 hours. Reactions take place in acid environment, e.g. hydrobromic acid, or in neutral environment. The obtained product can be processed in the usual way. It is further possible to convert the obtained compounds of formula I in other compounds of formula I.

The following examples illustrate the synthesis of compounds of the present invention but are never intended to limit the scope thereof.

EXAMPLE 1

Synthesis of N-benzyl-S-�2-(imidazol-4-yl)ethyl!isothiourea dipicrate (VUF 9028).

3.5 gram (13.7 mmol) 4(5)-(2-bromoethyl) imidazole.HBr and 2.3 gram N-benzylthiourea were refluxed for 60 hours in 30 ml ethanol. The ethanol was evaporated and the product was purified by means of column chromatography, using methanol/ethylacetate as eluent.

Subsequently the solvent was evaporated and the residue dissolved in methanol whereto 10 gram picric acid in methanol was added. After addition of water an oil was formed, which after stirring with water became solid. The solid matter with melting point 166.9.degree.-169.8.degree. C. was subsequently filtrated. The NMR-results of this compound are given in table 1.

EXAMPLE 2

Synthesis of S-�.omega.-(4(5)-imidazolyl)alkyl!-N-(.omega.-(substituted)-arylalkyl)isothiourea-derivatives.

Analogous to the preparation method of VUF 9028 from example 1 a number of compounds were synthesized with the formula: ##STR8## The meaning of n, m and R, the solvent of the condensation reaction and the melting points of the compounds are given in the table below. The NMR-results are given in table 1.

______________________________________ sol-Compound R.sub.2 R n m meltpoint salt vent______________________________________VUF 8397 H C.sub.6 H.sub.5 0 2 174-176.degree. C. 2HBr 2- prop.VUF 9029 H C.sub.6 H.sub.5 2 2 177-185.degree. C. 2HBr eth.VUF 9030 H C.sub.6 H.sub.5 3 2 152-155.degree. C. dipicr. eth.VUF 9031 H C.sub.6 H.sub.5 4 2 136-139.degree. C. 2HBr eth.VUF 9051 CH.sub.3 C.sub.6 H.sub.5 2 2 152-156.degree. C. 2HBr eth.VUF 9107 H C.sub.6 H.sub.5 1 3 155-160.degree. C. 2HBr eth.VUF 9151 H C.sub.6 H.sub.5 2 3 178-183.degree. C. 2HBr eth.VUF 9152 H C.sub.6 H.sub.5 3 3 177-184.degree. C. 2HBr eth.VUF 9153 H 4-ClC.sub.6 H.sub.4 1 3 200-205.degree. C. 2HBr eth.VUF 9163 H c-C.sub.6 H.sub.11 1 3 137-153.degree. C. dipicr. eth.VUF 4571 H C.sub.6 H.sub.5 4 3 112-134.degree. C. dipicr. eth.VUF 4586 H 4-IC.sub.6 H.sub.4 * 2 3 188-190.degree. C. 2HBr 2- prop.______________________________________ *Radioactively labeled compound, e.g. for use as a tracer

EXAMPLE 3

Synthesis of N-�2-(imidazol-4-yl)ethyl!-N'-phenyl guanidine dipicrate (VUF 9006).

Step 1:

Synthesis of S-ethyl-N-phenylisothiourea.

4 gram N-phenylisothiourea (33 mmol) and 5 ml ethyl bromide were refluxed for 10 hours in ethanol. Again 5 ml ethyl bromide was added. The reaction course was followed by thin layer chromatography (ethylacetate/petroleumether 3:7). Subsequently the solvent was evaporated and the residue crystallised from ethanol/ethylacetate.

Step 2:

15 mmol histamine.2HCl was added to 30 mmol sodium ethanolate in ethanol (prepared by dissolving 30 mmol sodium in ethanol). Subsequently it was refluxed for one half hour, after which the mixture was cooled in ice and the formed NaCl was filtrated.

To the filtrate 15 mmol S-ethyl-N-phenylisothiourea was added. Next the reaction mixture was refluxed for 35 hours (control with layer chromatography (ethyl acetate/petroleumether 1:1, saturated with ammonia)). Subsequently the solvent was evaporated and the residue dissolved in methanol. 35 mmol picric acid were added. The product was seperated by the addition of water and was subsequently crystallised from methanol/water. The melting point was 235.degree.-238.degree. C.

Analogous to the synthesis of VUF 9006 N-�2-(imidazol-4-yl)ethyl!-N'-phenyl-ethylguanidine dipicrate (VUF 9007; meltingpoint 196.degree.-198.degree. C.) was prepared. The NMR-results are given in table 1.

EXAMPLE 4

Synthesis of N-�.omega.-arylalkylthio)alkyl!-S-�.omega.-(imidazol-4-yl)alkyl!isothiourea- and -guanidine-derivatives.

Analogous to example 1 compounds were synthesized having the formula: ##STR9## The meaning of the symbols m, X and R, the solvent of the condensation reaction and the melting points of the compounds are given in the table below. The NMR-results are given in table 1.

______________________________________Compounds m X R melting point salt solvent______________________________________VUF 8404 2 S H 233-235.degree. C. 2HBr 2-prop.VUF 8405 3 NH H 145-148.degree. C. dipicr. ethanolVUF 8409 2 S C.sub.6 H.sub.5 106-109.degree. C. dipicr. ethanolVUF 8414 3 S H 126-133.degree. C. dipicr. ethanol______________________________________

EXAMPLE 5

Synthesis of N-alkyl-S-�.omega.-(4-imidazolyl)alkyl!isothiourea- and -guanidine-derivatives.

Analogous to example 1 compounds were synthesized having the formula: ##STR10## The meaning of the symbols m, X and R, the solvent of the condensation reaction and the melting points of the compounds are given in the table below. The NMR-results are given in table 1.

______________________________________Compound m X R melting point salt solvent______________________________________VUF 8325 2 S H 210-212.degree. C. 2HBr eth. VUF 83100 2 NH H 222-223.degree. C. 2HCl eth.VUF 8621 2 S CH.sub.3 180-181.degree. C. 2HBr water______________________________________

EXAMPLE 6

Synthesis of N-phenylalkyl-S-�.omega.-(4(5)imidazolyl)alkyl!isothiourea.2HBr (general procedure)

Compounds of the general formula: ##STR11## were prepared as follows.

X mmole 4(5)-(.omega.-bromoalkylimidazole).HBr and Y mmole N-(.omega.-phenylalkyl)isothiourea in absolute alcohol were added to a r.b. flask, provided with a cooler. The mixture was refluxed for 4 days. After that, the reaction mixture was evaporated and processed. The processing comprises flash chromatography (eluent: MeOH/ethyl acetate) followed by recrystallization from a suitable solvent. This yielded a white solid. According to this method the following compounds were synthesized with the parameters "X", "Y", solvent, yield, efficiency, melting point and NMR-results indicated.

1. N-(4-fluorobenzyl)-S-�3-(4(5)-imidazolyl)propyl!isothiourea.2HBr (VUF 4650)

X=20 mmole (5.40 g) Y=25 mmole (4.60 g) solvent: isopropanol yield: 1.75 g (19.8%) melting point: 176.0.degree.-187.0.degree. C. NMR-results: .sup.1 H-NMR (D.sub.2 O): .delta. 1.86-1.96 ppm (m, 2H, C-CH.sub.2 -C), 2.72-2.90 ppm (m, 2H, im-CH.sub.2), 3.13-3.28 ppm (m, 2H, S-CH.sub.2), 4.59 ppm (s, 2H, fenyl-CH.sub.2), 7.09-7.42 ppm (m, 6H, fenyl-H en im-H.sub.6), 8.60 ppm (s, 1H, im-H.sub.2).

2. N-�2-(4-chlorophenyl)ethyl!-S-�3-4(5)imidazolyl)propyl!isothiorea.2HBr (VUF 4657)

X=20 mmole (5.40 g) Y=25 mmole (5.37 g) Prior to recrystallization the crude compound was refluxed in 250 ml isopropanol and filtrated to remove organic contaminants. solvent: methanol yield after recrystallization from methanol: 2.58 g (27%) melting point: 205.2.degree. C. NMR-results: .sup.1 H-NMR (D.sub.2 O): .delta. 1.65-1.98 ppm-2.13 ppm (m, 2H, C-CH.sub.2 -C), 2.70 ppm (t, 2H, im-CH.sub.2), 2.82-3.10 ppm (m, 4H, N-CH.sub.2 +fenyl-CH.sub.2), 3.70 ppm (t, 2H, S-CH.sub.2), 7.10-7.40 ppm (m, 5H, fenyl-H en im-H.sub.5), 8.60 ppm (s, 1H, im-H.sub.2)

3. N-(4-bromobenzyl)-S-�3-(4(5)-imidazolyl)propyl!isothiourea.2HBr (VUF 4651)

X=14.1 mmole (3.80 g) Y=15.6 mmole (3.80 g) Prior to recrystallization the crude compound was refluxed in 250 ml isopropanol and filtrated to remove organic contaminants. solvent: methanol yield after recrystallization from methanol: 0.91 g (12.5%) melting point: 198.2.degree.-201.5.degree. C. NMR-results: .sup.1 H-NMR (D.sub.2 O): .delta. 2.00 ppm (m, 2H, C-CH.sub.2 -C), 2.80 ppm (m, 2H, im-CH.sub.2), 3.15 ppm (t, 2H, S-CH.sub.2), 4.55 ppm (a, 2H, Ar-CH.sub.2), 7.20 ppm (m, 3H, fenyl-H en im-H.sub.5), 7.55 ppm (d, 2H, fenyl-H),8.55 ppm (s, 1H, im-H.sub.2).

4. N-�2-(4-bromophenyl)ethyl!-S-�3-(4(5)-imidazolyl)propyl! isothiourea.2HBr (VUF 4598)

X=10 mmole (2.70 g) Y=13.3 mmole (3.44 g) Prior to recrystallization the crude compound was refluxed in 250 ml isopropanol and filtrated to remove organic contaminants. solvent: methanol yield after recrystallization from methanol: 1.63 g (23.3%) melting point: 202.2.degree.-203.5.degree. C. NMR-results: .sup.1 H NMR (D.sub.2 O): .delta. 1.62-1.85 ppm (m, 2H, C-CH.sub.2 -C), 2.70 ppm (m, 2H, im-CH.sub.2), 2.80-3.10 ppm (m, 4H, N-CH.sub.2 +Ar-CH.sub.2), 3.70 ppm (t, 2H, S-CH.sub.2), 7.10-7.50 ppm (2d+s, 5H, fenyl-H en im-H.sub.5), 8.60 ppm (s, 1H, im-H.sub.2).

5. N-(4-iodobenzyl)-S-�3-(4(5)-imidazolyl)propyl!isothiourea.2HBr (VUF 4652).

X=9.0 mmole (2.7 g) Y=12 mmole (3.5 g) solvent: isopropanol yield:0.79 g (18%) melting point: 190.degree.-192.7.degree. C. NMR-results: .sup.1 H-NMR (DMSO-d.sub.6): .delta. 1.99 ppm (m, 2H, C-CH.sub.2 -C), 2.84 ppm (t, 2H, im-CH.sub.2), 3.17 ppm (t, 2H, S-CH.sub.2), 4.54 ppm (s,2H, Ar-CH.sub.2), 7.05-7.18 ppm (m, 2H, fenyl-H), 7.19 ppm (d, 1H, im-H.sub.5), 7.70-7.85 ppm (m, 2H, fenyl-H), 8.46 ppm (d, 1H, im-H.sub.2).

6. N-�2-(4-iodophenyl)ethyl!-S-�3-(4(5)-imidazolyl)propyl!isothiourea.2HBr (VUF 4586)

X=5.0 mmole (1.53 g) Y=5.0 mmole (1.53 g) solvent: ethanol yield: 0.95 g (33%) melting point: 171.8.degree.-174.0.degree. C. NMR-results: .sup.1 -NMR (DMSO-d.sub.6); .delta. 1.89 ppm (m, 2H, C-CH.sub.2 -C), 2.74 ppm (t, 2H, Ar-CH.sub.2), 2.83 ppm (t, 2H, im-CH.sub.2), 3.24 ppm (t, 2H, N-CH.sub.2),3.57 ppm (t, 2H, S-CH.sub.2), 7.05-7.20 ppm (m, 2H, fenyl-H), 7.50 ppm (s, 1H, im-H.sub.5), 7.60-7.75 ppm (m, 2H, fenyl-H), 9.03 ppm (s, 1H, im-H.sub.2), 9.25 ppm (br s, 2H, N-H), 9.68 ppm (br s, 1H, NH), 14.05 ppm (br s, 2H, im-NH).

7. S-�3-(4(5)-imidazolyl)propyl!-N-(4-methylbenzyl) isothiourea.2HBr (VUF 4653)

X=20 mmole (5.40 g) Y=25 mmole (4.53 g) solvent: ethanol/ethylacetate yield: 1.37 g (15.2%) melting point: 1.92.degree.-198.7.degree. C. NMR-results: .sup.1 -NMR (D.sub.2 O): .delta. 1.95-2.15 ppm (m, 2H, C-CH.sub.2 -C), 2.45 ppm (s, 3H, CH.sub.3), 2.85 ppm (t, 2H, im-CH.sub.2), 3.18 ppm (t, 2H, S-CH.sub.2), 4.57 ppm (s, 2H, Ar-CH.sub.2), 7.22 ppm (s, 1H, im-H.sub.5), 7.30 ppm (s, 4H, fenyl-H), 8.56 ppm (s, 1H, im-H.sub.2).

8. S-�3-(4(5)-imidazolyl)propyl!-N-�2-(4-methylphenyl) ethyl!isothiourea.2HBr (VUF 4658)

X=20 mmole (5.40 g) Y=25 mmole (4.86 g) solvent: methanol yield: 1.57 g (17%) melting point: 211.2.degree.-214.5.degree. C. NMR-results: .sup.1 H-NMR (D.sub.2 O): .delta. 1.75-1.95 ppm (m, 2H, C-CH.sub.2 -C), 2.20 ppm (s, 3H, CH.sub.3), 2.75 ppm (t, 2H, im-CH.sub.2), 2.82-3.10 ppm (m, 4H, N-CH.sub.2 +Ar-CH.sub.2), 3.70 ppm (t, 2H, S-CH.sub.2), 7.10-7.25 ppm (m, 5H, fenyl-H+im-H.sub.5), 8.57 ppm (s, 1H, im-H.sub.2).

9. S-�3(4(5)-imidazolyl)propyl!-N-�2-(4-methoxybenzyl) isothiourea.2HBr (VUF 4654)

X=20 mmole (5.40 g) Y=20 mmole (3.93 g) solvent: ethanol yield: 2.69 g (29%) melting point: 181.0.degree.-184.0.degree. C. NMR-results: .sup.1 H-NMR (D.sub.2 O): .delta. 1.90-2.15 ppm (m, 2H, C-CH.sub.2 -C), 2.82 ppm (t, 2H, CH.sub.2 -im), 3.18 ppm (t, 2H, S-CH.sub.2), 3.70 ppm (s, SH, OCH.sub.3), 4.65 ppm (s, 2H, Ar-CH.sub.2), 6.90-7.45 ppm (2d+s, 5H, fenyl-H+im-H.sub.5), 8.60 ppm (s, 1H, im-H.sub.2).

10. S-�3-(4(5)-imidazolyl)propyl!-N-�2(4-methoxyphenyl) ethyl)!isothiourea.2HBr (VUF 4659)

X=20 mmole (4.21 g) Y=20 mmole (5.40 g) solvent: methanol yield: 2.84 g (30%) melting point: 171.8.degree.-174.2.degree. C. NMR-results: .sup.1 H-NMR (D.sub.2 O): .delta. 1.65-1.90 ppm (m,2H, C-CH.sub.2 -C), 2.67 ppm (t, 2H, CH.sub.2 -im), 2.80-3.05 ppm (m, 4H, N-CH.sub.2 +Ar-CH.sub.2), 3.65 ppm (s, 2H, S-CH.sub.2), 3.70 ppm (s, 3H, OCH.sub.3), 6.80-7.25 ppm (2d+s, 5H, fenyl-H+im-H.sub.5), 8.55 ppm (s, 1H, im-H.sub.2).

11. N-(3,4-dichlorobenzyl)-S-�3-(4(5)-imidazolyl)propyl! isothiourea.2HBr (VUF 4656).

X=20 mmole (4.60 g) Y=25 mmole (5.93 g) solvent: methanol yield: 1.51 g (15%) melting point: 213.9.degree.-214.4.degree. C. NMR-results: .sup.1 H-NMR (D.sub.2 O): .delta. 1.87-2.08 ppm (m, 2H, C-CH.sub.2 -C), 2.78 ppm (t, 2H, im-CH.sub.2), 3.15 ppm (t, 2H, S-CH.sub.2), 4.60 ppm (s, 2H, Ar-CH.sub.2), 7.12-7.80 ppm (m, H, fenyl-H en im-H.sub.5), 8.55 ppm (s, 1H, im-H.sub.2).

12. N-benzyl-S-�4-(4(5)-imidazolyl)butyl!isothiourea dipicrate (VUF 4661)

X=19.3 mmole (5.48 g) Y=19.3 mmole (3.22 g) It was not possible to recrystallize the endproduct as a diHBr salt. Therefore a dipicrate was prepared. For this the product was dissolved in 100 ml methanol and 2 eq. picric acid in 50 ml methanol were added dropwise while stiffing. Subsequently the product was precipitated by slowly adding water. A yellow solid crystallized which was filtrated. yield: 2.10 g (14.6%) melting point: 146.8.degree.-149.6.degree. C. NMR-results: .sup.1 H-NMR (DMSO-d.sub.6): .delta. 1.65 ppm (m, 4H, C-CH.sub.2 -CH.sub.2 -C),2.65 ppm (t, 2H, im-CH.sub.2), 3.20 ppm (t, 2H, S-CH.sub.2), 4.58 ppm (d, 2H, fenyl-CH.sub.2), 7.30-7.50 ppm (m, 6H, fenyl-H+im-H.sub.5), 8.60 ppm (s, 4H, picraat-H), 9.00 ppm (s, 1H, im-H.sub.2), 9.30 ppm (br s, 2H, =NH.sub.2), 10.00 ppm (t,1H, NH), 14.10 ppm (m, 2H, im-NH).

13. N-(2-phenylethyl)-S-�4-(4(5)-imidazolyl)butyl!isothiourea dipicrate (VUF 4662)

X=19.3 mmole (5.48 g) Y=19.3 mmole (3.49 g) Analogous to compound 12 a dipicrate was prepared. yield: 3.78 g (25.7%) melting point: 160.6.degree.-167.0.degree. C. NMR results: .sup.1 H-NMR (DMSO-d6): .delta. 1.62 ppm (m,4H, C-CH.sub.2 -CH.sub.2 -C),2.65 ppm(t, 2H, Ar-CH.sub.2), 2.85 ppm (t, 2H, im-CH.sub.2), 3.17 ppm (m, 2H, N-CH.sub.2), 3.55 ppm (m, 2H, S-CH.sub.2), 7.30 ppm (m, 5H, fenyl-H), 7.42 ppm (s, 1H, im-H.sub.5), 8.60 ppm (s, 4H, picraat-H), 9.00 ppm (s, 1H, im-H.sub.2), 9.20 ppm (br s, 2H, N=H), 9.62 ppm (t, 1H, NH), 14.05 ppm (m, 2H, im-NH).

The following table shows the above described compounds in summary and lists their antagonistic activity.

______________________________________X n m pA.sub.2 VUF code______________________________________H 4 1 8.72 4661H 4 2 8.13 46624-F 3 1 9.38 46504-Br 3 1 9.77 46514-I 3 1 9.21 46524-CH.sub.3 3 1 9.36 46534-OCH.sub.3 3 1 9.39 46543,4-Cl.sub.2 3 1 8.96 46564-Cl 3 2 9.2 46574-I 3 2 8.7 45864-CH.sub.3 3 2 8.4 46584-Br 3 2 9.0 45984-OCH.sub.3 3 2 8.3 4659______________________________________ TABLE 1______________________________________NMR-results of the compounds mentioned in thedescription.______________________________________COMPOUNDSAGONISTSVUF83253.06 ppm triplet J = 7.0 Hz 2H3.56 ppm triplet J = 7.0 Hz 2H7.61 ppm singlet 1H9.01-9.27 ppm multiplet 5HVUF86212.93 ppm singlet 3H3.07 ppm triplet J = 6.8 Hz 2H3.59 ppm triplet J = 6.8 Hz 2H7.60 ppm singlet 1H9.11 ppm doublet J = 1.3 Hz 1HANTAGONISTSVUF90283.06 ppm triplet J = 6.9 2H3.54 ppm triplet J = 6.9 2H4.58 ppm singlet 2H7.29-7.49 ppm multiplet 6H7.52 ppm singlet 4H8.62 ppm singlet 1H9.08 ppm doublet J = 1.3 Hz 1HVUF90292.90 ppm triplet J = 7.5 Hz 2H3.00 ppm triplet J = 7.0 Hz 2H3.50-3.69 ppm multiplet 4H7.21-7.35 ppm multiplet 5H7.58 ppm singlet 1H9.16 ppm doublet J = 1.3 Hz 1HVUF90301.86 ppm quintet J = 7.4 Hz 2H2.62 ppm triplet J = 7.4 Hz 2H3.05 ppm triplet J = 6.9 Hz 2H3.24-3.38 ppm multiplet 2H3.51 ppm triplet J = 6.9 Hz 2H7.16-7.39 ppm multiplet 5H7.53 ppm singlet 1H8.61 ppm singlet 4H9.06 ppm doublet J = 1.3 Hz 1HVUF90311.45-1.71 ppm multiplet 4H2.60 ppm triplet 2H3.05 ppm triplet J = 6.8 Hz 2H3.30-3.45 ppm multiplet 2H3.60 ppm triplet J = 6.8 Hz 2H7.13-7.46 ppm multiplet 5H7.60 ppm singlet 1H9.13 ppm doublet J = 1.4 Hz 1HVUF90512.80-3.06 ppm multiplet 4H3.50-3.68 ppm multiplet 4H7.18-7.40 ppm multiplet 5H7.57 ppm singlet 1H9.09 ppm singlet 1HVUF90062.90 ppm triplet J = 6.3 Hz 2H3.51 ppm triplet J = 6.3 Hz 2H7.14-7.50 ppm multiplet 5H7.69-7.86 ppm multiplet 2H8.59 ppm singlet 4H8.97 ppm singlet 1HVUF90072.74-2.92 ppm multiplet 4H3.32-3.51 ppm multiplet 4H7.18-7.50 ppm multiplet 6H8.63 ppm singlet 4H9.05 ppm doublet 1HVUF84042.66 ppm triplet J = 6.3 Hz 2H3.06 ppm triplet J = 6.3 Hz 2H3.40-3.72 ppm multiplet 4H3.81 ppm singlet 2H7.28 ppm singlet 5H7.58 ppm singlet 1H9.07 ppm doublet J = 0.8 Hz 1HVUF84051.64 ppm quintet J = 7.2 Hz 2H2.38-2.84 ppm multiplet 4H3.06-3.56 ppm multiplet 4H3.80 ppm singlet 2H7.26-7.44 ppm multiplet 6H8.60 ppm singlet 4H9.02 ppm singlet 1HVUF84092.56 ppm triplet J = 6.8 Hz 2H3.03 ppm triplet J = 6.8 Hz 2H3.26-3.70 ppm multiplet 4H5.40 ppm singlet 1H7.10-7.56 ppm multiplet 11H8.60 ppm singlet 4H9.02 ppm singlet 1HVUF84141.94 ppm quintet J = 6.8 Hz 2H2.60-2.94 ppm multiplet 4H3.20 ppm triplet J = 6.8 Hz 2H3.30-3.68 ppm multiplet 2H3.78 ppm singlet 2H7.28-7.42 ppm multiplet 6H8.60 ppm singlet 4H9.00 ppm doublet J = 1.0 Hz 1HVUF91071.86-2.05 ppm multiplet 2H2.76 ppm triplet J = 7.5 Hz 2H3.20-3.51 ppm multiplet 7H4.60 ppm singlet 2H7.26-7.52 ppm multiplet 6H9.01 ppm doublet J = 1.3 Hz 1HVUF91511.81-1.98 ppm multiplet 2H2.73 ppm triplet J = 7.5 Hz 2H2.89 ppm triplet J = 7.0 Hz 2H3.22 ppm triplet J = 7.0 Hz 2H3.34 ppm singlet 6H3.52-3.68 ppm multiplet 2H7.20-7.40 ppm multiplet 5H7.48 ppm singlet 1H9.02 ppm doublet J = 1.3 Hz 1HVUF91521.78-2.06 ppm multiplet J = 7.6 Hz 4H2.64 ppm triplet J = 7.3 Hz 2H2.77 ppm triplet 2H3.19-3.50 ppm multiplet 10H7.18-7.40 ppm multiplet 5H7.49 ppm singlet 1H9.01 ppm doublet J = 1.3 Hz 1HVUF91531.86-2.06 ppm multiplet J = 7.2 Hz 2H2.77 ppm triplet 2H3.22-3.49 ppm multiplet 6H4.60 ppm singlet 2H7.32-7.58 ppm multiplet 6H9.04 ppm doublet J = 1.3 Hz 1HVUF91630.80-1.77 ppm multiplet 11H1.86-2.03 ppm multiplet 2H2.74 ppm triplet J = 7.0 Hz 2H3.08-3.25 ppm multiplet 4H3.35 ppm singlet 10H7.46 ppm singlet 1H8.49 ppm singlet 4H8.98 ppm doublet J = 1.3 Hz 1HVUF45711.47-1.70 ppm multiplet 4H1.84-2.03 ppm multiplet 2H2.42-2.66 ppm multiplet 50H2.74 ppm triplet J = 7.2 Hz 2H3.19 ppm triplet J = 7.2 Hz 2H3.26-3.38 ppm multiplet 2H3.46 ppm multiplet 10H7.11-7.35 ppm multiplet 5H7.47 ppm singlet 1H8.59 ppm singlet 4HVUF45861.89 ppm multiplet 2H2.74 ppm triplet J = 7.2 Hz 2H2.83 ppm triplet J = 7.0 Hz 2H3.24 ppm multiplet 2H3.57 ppm multiplet J = 7.2 Hz 2H7.05-7.20 ppm multiplet 2H7.60-7.75 ppm multiplet 2H7.50 ppm singlet 1H9.03 ppm singlet 1H______________________________________ Pharmacological experiments

The agonistics and antagonistics activities on the H.sub.3 -receptor of the various compounds were determined compared to histamine. The test methods used therefor are described in Van der Werf et al., Agents and Actions 20, 3/4 (1987) p. 239-243 and Menkveld et al., European Journal of Pharmacology, 186 (1990) p. 343-347.

The results of the experiments are given in the tables below. pD.sub.2 is the negative logarithm of the concentration of the test compound at which 50% agonistic activity was measured. pA.sub.2 is the negative logarithm of the concentration of the test compound at which the concentration of the agonist had to be doubled to obtain the same effect as obtained when the antagonist was absent.

Pharmaceutical compositions, comprising compounds of formula I as defined in claim 19 as the active ingredient for therapeutically influencing the human and animal histaminergic system have the form of powders, suspensions, solutions, sprays, emulsions, unguents or creams and can be used for local application, intranasal, rectal, vaginal and also for oral or parenteral (intravenous, intradermal, intramusculer, intrathecal etc.) administration. Such compositions can be prepared by combining (i.e. by mixing, dissolving etc.) of the active compound of formula I in the form of a free acid or salt with pharmaceutically acceptable excipients with neutral character (such as aquous or non-aquous solvents, stabilizers, emulsifiers, detergents, additives), and further if necessary colouring agents and flavouring agents. The concentration of the active ingredient in a pharmaceutical composition can vary between 0.1% and 100%, depending on the nature of the influence and the method of administration. The dose of the active ingredient that is administered can further be varied between 0.1 mg and 100 mg per kg bodyweight.

TABLE 2______________________________________Antagonistic activityCompound pA.sub.2 test method______________________________________VUF 8397 7.0 rat cortexVUF 9028 7.8 ileum guinea pigVUF 9029 8.0 ileum guinea pigVUF 9030 7.6 ileum guinea pigVUF 9031 7.7 ileum guinea pigVUF 9051 7.8 ileum guinea pigVUF 9006 5.8 ileum guinea pigVUF 9007 6.3 ileum guinea pigVUF 8404 7.4 ileum guinea pigVUF 8405 7.9 ileum guinea pigVUF 8409 6.6 ileum guinea pigVUF 8414 8.6 ileum guinea pigVUF 9107 8.8 ileum guinea pigVUF 9151 8.8 ileum guinea pigVUF 9152 8.3 ileum guinea pigVUF 9153 9.9 ileum guinea pigVUF 9163 8.8 ileum guinea pigVUF 4571 8.4 ileum guinea pigVUF 4586 9.2 ileum guinea pig______________________________________ TABLE 3______________________________________Agonistic activityCompound pD.sub.2 test method______________________________________VUF 8325 9.3 rat cortexVUF 8325 8.1 ileum guinea pig VUF 83100 7.4 rat cortexVUF 8621 7.3 ileum guinea pig______________________________________

Claims

1. A compound of the formula: ##STR12## wherein, n is 3, and R is selected from the group consisting of (4-fluorobenzyl), �2-(4-chlorophenyl)ethyl!, (4-bromobenzyl), �2-(4-bromophenyl)ethyl!, (4-iodobenzyl), �2-(4-iodophenyl)ethyl!, �2-(4-methoxybenzyl)!, �2(4-methoxyphenyl)ethyl! and (3,4-dichlorobenzyl) and a salt, selected from the group consisting of 2HBr and dipicrate.

2. An imidazole derivative wherein said derivative is N-cyclohexylmethyl-S-�3-(4(5)-imidazoyl)propyl!isothiourea.

3. An imidazole derivative wherein said derivative is N-�2-(benzylthio)ethyl!-S-�3-(imidazoyl-4-yl)propyl!isothiourea.

4. A pharmaceutical composition comprising a suitable excipient and as an active ingredient the compound of claim 3 or a pharmacologically acceptable salt thereof, wherein said active ingredient is between 0.1% to 100% of said pharmaceutical composition.

5. A method for preparing the compound of claim 1 by condensation of 4(5)-(.omega.-bromoalkylimidazole).multidot.HBr and N-(.omega.-phenylalkyl)isothiourea.

6. A pharmaceutical composition comprising a suitable excipient and as an active agent a compound as recited in claim 1 wherein said active ingredient is between 0% and 100% of said pharmaceutical composition.

7. A pharmaceutical composition comprising a suitable excipient and as an active ingredient the compound of claim 3 or a pharmacologically acceptable salt thereof, wherein said active ingredient is between 0.1% to 100% of said pharmaceutical composition.

8. A method of inducing agonistic or antagonistic activity of histamine H.sub.3 -receptors in a patient in need thereof which comprises administering to said patient a pharmaceutical composition having agonistic or antagonistic activity on the histamine H.sub.3 -receptor, wherein said pharmaceutical composition is the composition of claim 4.

9. A method of inducing agonistic or antagonistic activity of histamine H.sub.3 -receptors in a patient in need thereof which comprises administering to said patient a pharmaceutical composition having agonistic or antagonistic activity on the histamine H.sub.3 -receptor, wherein said pharmaceutical composition is the composition of claim 7.

10. The complex as claimed in claim 1, wherein the compound is N-(4-fluorobenzyl)-S-�.omega.-(4(5)imidazolyl)propyl!isothiourea and the salt is 2HBr.

11. The complex as claimed in claim 1, wherein the compound is N-�2-(4-chlorophenyl)ethyl!-S-�.omega.-(4(5)imidazolyl)propyl!isothiourea and the salt is 2HBr.

12. The complex as claimed in claim 1, wherein the compound is N-(4-bromobenzyl)-S-�.omega.-(4(5)imidazolyl)propyl!isothiourea and the salt is 2HBr.

13. The complex as claimed in claim 1, wherein the compound in N-�2-(4-bromophenyl)ethyl!-S-�.omega.-(4(5)imidazolyl)propyl!isothiourea and the salt is 2HBr.

14. The complex as claimed in claim 1, wherein the compound is N-(4-iodobenzyl)-S-�.omega.-(4(5)imidazolyl)propyl!isothiourea and the salt is 2HBr.

15. The complex as claimed in claim 1, wherein the compound is N-�2-(4-iodophenyl)ethyl!-S-�.omega.-(4(5)imidazolyl)propyl!isothiourea and the salt is 2HBr.

16. The complex as claimed in claim 1, wherein the compound is N-�2-(4-methoxybenzyl)!-S-�.omega.-(4(5)imidazolyl)propyl!isothiourea and the salt is 2HBr.

17. The complex as claimed in claim 1, wherein the compound is N-�2-(4-methoxyphenyl)ethyl!-S-�.omega.-(4(5)imidazolyl)propyl!isothiourea and the salt is 2HBr.

18. The complex as claimed in claim 1, wherein the compound is N-(3,4-dichlorobenzyl)-S-�.omega.-(4(5)imidazolyl)propyl!isothiourea and the salt is 2HBr.